Moreover, a phase I clinical trial that combines anti-GPC3 antibody with immune checkpoint inhibitors (anti-PD-L1 antibodies) has shown well-tolerated immune response and potential anti-tumor activity in GPC3-overexpressing HCC. Here, GPC3 is linked to hepatocellular carcinoma.